Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
Kura Oncology, Inc. (KURA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript
Kura Oncology Q1 Earnings Call Highlights
Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates
Kura Oncology Reports First Quarter 2026 Financial Results
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
Kura Oncology to Report First Quarter 2026 Financial Results
Kura Oncology to Report First Quarter 2026 Financial Results
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
Kura Oncology: Poised For A Lift With Combinations
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data
Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last?
Kura Oncology (NASDAQ:KURA) Trading Up 9.7% – Here’s What Happened
Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell Carcinoma Transcript
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
Kura Oncology, Inc. $KURA Shares Bought by SG Americas Securities LLC
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology: Commercialization In AML Presents Asymmetric Upside
Kura Oncology, Inc. (KURA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Kura Oncology Q4 Earnings Call Highlights
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology (NASDAQ:KURA) Shares Gap Down After Earnings Miss
Kura Oncology, Inc. (KURA) Q4 2025 Earnings Call Transcript
Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
Kura Oncology to Participate in Three Upcoming Investor Conferences
Earnings Preview: Kura Oncology (KURA) Q4 Earnings Expected to Decline
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy
New Strong Sell Stocks for January 21st
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of “Moderate Buy” by Brokerages
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Kura Oncology: A Cautious Buy
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
AXQ Capital LP Raises Stock Position in Kura Oncology, Inc. $KURA
Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript
Kura Oncology (NASDAQ:KURA) Sees Strong Trading Volume on Analyst Upgrade